Published in J Clin Oncol on April 10, 2008
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med (2016) 1.55
Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. Cancer (2015) 1.42
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer (2013) 1.37
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer (2009) 1.25
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer (2012) 1.13
Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg (2013) 1.10
An update on chemotherapy of colorectal liver metastases. World J Gastroenterol (2012) 1.05
Treatment of colorectal liver metastases. World J Surg Oncol (2011) 1.04
Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol (2011) 1.04
Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. HPB (Oxford) (2012) 1.01
Recent advances in the curative treatment of colorectal liver metastases. Gastrointest Cancer Res (2011) 1.00
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer (2011) 1.00
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol (2009) 1.00
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap Adv Gastroenterol (2013) 0.98
Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? World J Gastroenterol (2014) 0.97
Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation. Surg Endosc (2010) 0.97
Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol (2011) 0.95
Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist (2011) 0.95
Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res (2011) 0.93
Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg (2009) 0.93
Colorectal liver metastases. Int J Surg Oncol (2011) 0.93
Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB (Oxford) (2010) 0.91
Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg (2010) 0.90
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer (2010) 0.90
Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol (2010) 0.87
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer (2009) 0.87
Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy? Support Care Cancer (2014) 0.87
Severe hypotony and filtering bleb leak after intravitreal injection of ranibizumab. Ther Clin Risk Manag (2009) 0.86
Accomplishments in 2008 in the management of curable metastatic colorectal cancer. Gastrointest Cancer Res (2009) 0.86
Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. Br J Cancer (2012) 0.85
Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol (2011) 0.85
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer (2013) 0.85
The effect of bevacizumab on colon anastomotic healing in rats. Int J Colorectal Dis (2010) 0.84
Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. World J Gastroenterol (2014) 0.83
Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. PLoS One (2014) 0.83
Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections. HPB (Oxford) (2012) 0.83
Optimal timing of systemic therapy in resectable colorectal liver metastases. Am Surg (2013) 0.83
A patient who showed a pathologically complete response after undergoing treatment with XELOX plus bevacizumab for synchronous liver metastasis of grade H2 from sigmoid colon cancer. J Gastrointest Oncol (2013) 0.82
Tumour growth after portal vein embolization with pre-procedural chemotherapy for colorectal liver metastases. HPB (Oxford) (2015) 0.82
Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). Onco Targets Ther (2015) 0.82
Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer. Bioconjug Chem (2010) 0.81
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer (2012) 0.81
Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol (2011) 0.80
GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study. BMC Cancer (2015) 0.79
Outcome after repeat resection of liver metastases from colorectal cancer. Int J Colorectal Dis (2013) 0.79
Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D (2011) 0.79
Anti-angiogenic agents in metastatic colorectal cancer. World J Gastrointest Oncol (2015) 0.79
Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am (2010) 0.78
Systemic treatment of liver metastases from colorectal cancer. Ther Adv Med Oncol (2013) 0.78
Curative strategies for liver metastases from colorectal cancer: a review. Oncologist (2012) 0.78
How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol (2014) 0.78
Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol (2015) 0.78
Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin. PLoS One (2013) 0.78
Role of surgery in colorectal liver metastases: too early or too late? World J Gastroenterol (2010) 0.78
Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis. Oncotarget (2015) 0.78
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer (2015) 0.77
Neoadjuvant therapy before surgical treatment. EJC Suppl (2013) 0.77
The aspartate aminotransferase to platelet ratio before chemotherapy predicts adverse events for FOLFOX and XELOX regimens including bevacizumab as the first-line therapy for stage IV, recurrent and metastatic colorectal cancer. J Gastrointest Oncol (2013) 0.77
Surgical options for initially unresectable colorectal liver metastases. HPB Surg (2012) 0.77
Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World J Gastroenterol (2009) 0.77
Management of potentially resectable colorectal cancer liver metastases. World J Gastrointest Surg (2013) 0.77
Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. Pharmacogenomics J (2015) 0.77
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer (2015) 0.76
Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol (2014) 0.76
Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review. World J Gastroenterol (2014) 0.76
A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. Onco Targets Ther (2014) 0.76
Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther (2012) 0.76
Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol (2010) 0.75
Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncol Rev (2012) 0.75
Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases. Am J Clin Oncol (2016) 0.75
Risks and benefits with bevacizumab: evidence and clinical implications. Ther Adv Drug Saf (2012) 0.75
Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients with Colorectal Liver Metastases. Ann Surg Oncol (2016) 0.75
Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer? Ann Transl Med (2013) 0.75
Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surg Oncol (2016) 0.75
The role of peri-operative treatment in resectable liver metastases of colorectal cancer. Ther Adv Med Oncol (2010) 0.75
Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol (2016) 0.75
Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer. Oncoimmunology (2017) 0.75
Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings. Ann Surg Oncol (2015) 0.75
Proposal for novel histological findings of colorectal liver metastases with preoperative chemotherapy. Pathol Int (2015) 0.75
Surgical management of colorectal cancer metastases to the liver: multimodality approach and a single institutional experience. Colorectal Cancer (2013) 0.75
A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach. Med Oncol (2014) 0.75
Pathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases: a report of an unusual case. Surg Case Rep (2016) 0.75
A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer. Chin J Cancer Res (2016) 0.75
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. Target Oncol (2016) 0.75
Trials on preoperative chemotherapy in resectable colorectal liver metastases need prospective evaluation of predictive factors of response. J Clin Oncol (2008) 0.75
Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases: a retrospective cohort study. Medicine (Baltimore) (2016) 0.75
Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX. Surg Endosc (2010) 0.75
Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis. Langenbecks Arch Surg (2017) 0.75
Influence of preoperative chemotherapy on CT volumetric liver regeneration following right hemihepatectomy. World J Surg (2014) 0.75
The effects of bevacizumab on intestinal anastomotic healing in rabbits. Surg Today (2016) 0.75
Hepatectomy for Colorectal Cancer Liver Metastases in the Era of Modern Preoperative Chemotherapy: Evaluation of Postoperative Complications. World J Surg (2016) 0.75
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (2009) 7.50
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med (2005) 6.22
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol (2008) 5.78
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol (2009) 5.57
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol (2009) 5.11
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68
Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology (2014) 4.00
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol (2011) 3.51
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood (2008) 2.97
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol (2006) 2.51
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol (2008) 2.46
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer (2006) 2.40
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol (2010) 2.36
Prediction of venous thromboembolism in cancer patients. Blood (2010) 2.31
Use of a peripheral venous catheter in single-incision laparoscopic surgery. Surg Endosc (2010) 2.04
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol (2010) 1.80
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol (2009) 1.78
High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica (2012) 1.62
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer (2007) 1.58
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Clinical benefit response in pancreatic cancer trials revisited. Oncol Res Treat (2014) 1.43
Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol (2008) 1.39
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol (2010) 1.36
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol (2010) 1.32
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer (2006) 1.31
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer (2011) 1.30
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood (2004) 1.30
Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer (2005) 1.27
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer (2008) 1.26
Crohn's disease of the appendix. Virchows Arch (2001) 1.21
Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res (2005) 1.21
Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol (2012) 1.19
Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol (2011) 1.17
Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol (2010) 1.16
Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant (2008) 1.14
Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res (2005) 1.13
Balance between NF-kappaB and JNK/AP-1 activity controls dendritic cell life and death. Blood (2005) 1.12
Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol (2010) 1.10
Endorectal advancement flaps in the treatment of high anal fistula of cryptoglandular origin: full-thickness vs. mucosal-rectum flaps. Dis Colon Rectum (2008) 1.08
Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol (2007) 1.07
Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.07
Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res (2007) 1.04
Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol (2006) 1.01
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer (2011) 1.01
Mild hypercapnia increases subcutaneous and colonic oxygen tension in patients given 80% inspired oxygen during abdominal surgery. Anesthesiology (2006) 1.00
Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis (2004) 0.99
Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies. Anticancer Drugs (2003) 0.99
Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. Int J Cancer (2007) 0.99
TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg (2002) 0.98
NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery (2010) 0.96
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica (2011) 0.95
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Ann Surg Oncol (2011) 0.95
Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma. J Proteome Res (2013) 0.95
Mortality and complications after stoma closure. Arch Surg (2005) 0.94
Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica (2013) 0.93
Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg (2010) 0.92
Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection. Ann Surg Oncol (2011) 0.92
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol Cancer Ther (2009) 0.91
An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion (2003) 0.91
Conventional laparoscopy vs. single port surgery from a patient's point of view: influence of demographics and body mass index. Wien Klin Wochenschr (2012) 0.91
Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial. BMC Anesthesiol (2009) 0.91
Complications after free flap surgery: do we need a standardized classification of surgical complications? Br J Oral Maxillofac Surg (2011) 0.91
Quantitative analysis of gene expression in human articular chondrocytes in monolayer culture. Int J Mol Med (2004) 0.91
Bevacizumab treatment for advanced breast cancer. Oncologist (2011) 0.90
Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res (2008) 0.90
Gastrointestinal autonomic nerve tumors: a surgical point of view. World J Gastroenterol (2004) 0.90
Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res (2009) 0.90
Nitrous oxide and risk of surgical wound infection: a randomised trial. Lancet (2005) 0.89
Long-term anorectal and sexual function after overlapping anterior anal sphincter repair: a case-match study. Dis Colon Rectum (2009) 0.89
Post-treatment imaging of liver tumours. Cancer Imaging (2007) 0.89
Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost (2013) 0.89
Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am J Surg (2005) 0.89
Circulating procoagulant microparticles in cancer patients. Ann Hematol (2010) 0.89
Survival of women with breast cancer in Austria by age, stage and period of diagnosis. Wien Klin Wochenschr (2002) 0.88